GlaxoSmithKline News and Research

RSS

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.

11 Apr 2013

GSK, A*STAR's ICES to develop new evidence based formulations for emerging markets

GlaxoSmithKline and A*STAR's Institute of Chemical and Engineering Sciences have signed a five-year strategic agreement to develop new evidence based formulations specifically for emerging markets.

9 Apr 2013

American Society of Hematology announces first recipients of ASH Bridge Grants

The American Society of Hematology, the world's largest professional organization dedicated to the causes and treatment of blood disorders, today announced the first recipients of the ASH Bridge Grants, a new award program designed to help hematologists continue their critical blood disease research amid severe funding reductions for the National Institutes of Health.

9 Apr 2013

GlaxoSmithKline opens new facility in Philadelphia's Navy Yard Corporate Center

GlaxoSmithKline officially opened its new double LEED® platinum certified facility in Philadelphia's Navy Yard Corporate Center today, ushering in a new era of how people work in Philadelphia.

8 Apr 2013

Effectiveness of candidate malaria vaccine decreases over time, study shows

"The effectiveness of an experimental malaria vaccine developed by GlaxoSmithKline wanes over time, with the shot protecting only 16.8 percent of children over four years, according to trial data," Reuters reports.

22 Mar 2013

Migraine severity may be predicted by blood levels of fat cell hormone

In a small, preliminary study of regular migraine sufferers, scientists have found that measuring a fat-derived protein called adiponectin (ADP) before and after migraine treatment can accurately reveal which headache victims felt pain relief.

18 Mar 2013

CEOs of 27 companies write open letter urging British PM to keep foreign aid commitment

"Chief executives of 27 [of the] biggest companies in the U.K., including BP and Vodafone, [on Monday] joined the boss of English football's Premier League in appealing to Prime Minister David Cameron to keep his commitment to devote 0.7 percent of national income on international aid," the Press Trust of India/Business Standard reports (3/11).

13 Mar 2013

Drugs that combat ageing may be available within five years

Drugs that combat ageing may be available within five years, following landmark work led by an Australian researcher.

11 Mar 2013

Weekend reading: Deciding if it's 'time to let mom die,' a cancer hospital's controversial admission procedures

My father, sister and I sat in the near-empty Chinese restaurant, picking at our plates, unable to avoid the question that we'd gathered to discuss: When was it time to let Mom die? ... My father and sister looked to me for my thoughts. In our family, after all, I'm the go-to guy for all things medical. I've been a health care reporter for 15 years: at the Dallas Morning News, the Los Angeles Times and now ProPublica.

7 Mar 2013

GlaxoSmithKline's HIV/AIDS business joins Medicines Patent Pool

"GlaxoSmithKline's HIV/AIDS drugs business is to share intellectual property rights on children's medicine in a patent pool designed to make treatments more widely available in poor countries," Reuters reports.

1 Mar 2013

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

23 Feb 2013

GSK1322322 targets gram-positive bacteria including methicillin-resistant strains of MRSA

An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.

14 Feb 2013

Targacept reports net loss of $15.9 million for fourth quarter 2012

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the fourth quarter and year ended December 31, 2012.

14 Feb 2013

GSK, Vanderbilt partner to develop and commercialize new therapies for severe obesity

Vanderbilt University announced today that it has signed a collaboration agreement with GlaxoSmithKline (GSK) for the discovery, development and commercialization of novel therapies for severe obesity.

13 Feb 2013

GAVI Alliance to fund HPV immunization projects in 8 countries

The GAVI Alliance "is to help protect more than 180,000 girls in eight countries across Africa and Asia from cervical cancer by funding immunization projects with vaccines from Merck and GlaxoSmithKline," Reuters reports in an article examining the group's efforts to vaccinate young women with Merck's Gardasil and GSK's Cervarix, "the world's only two approved shots designed to protect against the sexually transmitted human papillomavirus (HPV) that causes the vast majority of cervical cancer cases."

5 Feb 2013

MSF claims aid for vaccines subsidizing pharmaceutical companies, Guardian reports

"Large sums of public money intended to ensure children in the developing world are immunized against disease are effectively being used to subsidize Big Pharma, doctors working in the field claim," the Guardian reports.

5 Feb 2013

Perrigo introduces generic Olux-E Foam, 0.05%

Perrigo Company today announced that it has launched clobetasol emulsion propionate foam, 0.05%, the generic equivalent of Olux -E Foam, 0.05%.

1 Feb 2013

Indian company plans to make lower-cost injectable polio vaccine

Serum Institute of India Ltd., the world's largest vaccine manufacturer, plans to "slash the price of polio immunization and introduce shots for diarrhea and pneumonia, undercutting Pfizer Inc. and GlaxoSmithKline Plc.," Bloomberg Businessweek reports.

24 Jan 2013

Studies identify cellular pathways involved in governing day-night pattern of circadian rhythms

UC Irvine-led studies have revealed the cellular mechanism by which circadian rhythms - also known as the body clock - modify energy metabolism and also have identified novel compounds that control this action. The findings point to potential treatments for disorders triggered by circadian rhythm dysfunction, ranging from insomnia and obesity to diabetes and cancer.

23 Jan 2013

Ceram to develop its Controlled Release Technology for the delivery of selected AstraZeneca compounds

AstraZeneca, a global pharmaceutical company, has signed an agreement with Ceram Research Ltd, the international materials development company, for Ceram to develop its Inorganic-based Controlled Release Technology in a feasibility study for the delivery of selected AstraZeneca compounds.

18 Jan 2013